Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 388

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 388
---
 December
    31,  
    December
    31, 

    2024  
    2023 
  
    ASSETS 

    Current assets: 

    Cash 
    $1,266,131  
    $1,231 
  
    Deferred offering costs 
     -  
     303,281 
  
    Prepaid expenses 
     57,874  
     713 
  
    Due
    from related parties 
     -  
     130,000 
  
    Total current assets 
     1,324,005  
     435,225 

    Deferred financing costs 
     -  
     4,338,543 

    Total
    assets 
    $1,324,005  
    $4,773,768 

    LIABILITIES AND STOCKHOLDERS’
    EQUITY 

    Current liabilities: 

    Trade accounts payable
    and accrued liabilities 
    $587,536  
    $707,187 
  
    Due to related parties 
     93,432  
     527,377 
  
    Related
    party line of credit 
     -  
     101,000 
  
    Total current liabilities 
     680,968  
     1,335,564 

    Total liabilities 
     680,968  
     1,335,564 

    Stockholders’ Equity 

    Preferred Stock, no par
    value, 100,000,000 shares authorized and none issued or outstanding. 
     -  
     - 
  
    Common Stock, no par value;
    300,000,000 shares authorized, 29,762,671 and 28,609,814 shares issued and outstanding at December 31, 2024 and December 31, 2023,
    respectively. 
     -  
     - 
  
    Additional paid-in capital 
     31,239,895  
     17,502,346 
  
    Accumulated
    deficit 
     (30,596,858) 
     (14,064,142)
  
    Total
    stockholders’ equity 
     643,037  
     3,438,204 
  
    Total
    liabilities and stockholders’ equity 
    $1,324,005  
    $